Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - GW PHARMACEUTICALS PLC | gwph-ex321_93.htm |
| EX-31.2 - EX-31.2 - GW PHARMACEUTICALS PLC | gwph-ex312_92.htm |
| EX-31.1 - EX-31.1 - GW PHARMACEUTICALS PLC | gwph-ex311_91.htm |
| EX-23.2 - EX-23.2 - GW PHARMACEUTICALS PLC | gwph-ex232_88.htm |
| EX-23.1 - EX-23.1 - GW PHARMACEUTICALS PLC | gwph-ex231_89.htm |
| EX-14.1 - EX-14.1 - GW PHARMACEUTICALS PLC | gwph-ex141_94.htm |
| EX-10.82 - EX-10.82 - GW PHARMACEUTICALS PLC | gwph-ex1082_77.htm |
| EX-10.81 - EX-10.81 - GW PHARMACEUTICALS PLC | gwph-ex1081_75.htm |
| EX-10.80 - EX-10.80 - GW PHARMACEUTICALS PLC | gwph-ex1080_76.htm |
| EX-3.1 - EX-3.1 - GW PHARMACEUTICALS PLC | gwph-ex31_160.htm |
| 10-K - 10-K - GW PHARMACEUTICALS PLC | gwph-10k_20180930.htm |
Exhibit 16.1
November 28, 2018
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 9 of GW Pharmaceuticals plc’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 28, 2018, and we agree with the statements made therein.
Yours truly,
/s/ Deloitte LLP
London, United Kingdom
AMECURRENT 730651623.1 27-Nov-18 15:34